Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Ultragenyx Pharmaceu (RARE)

Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,699,494
  • Shares Outstanding, K 92,165
  • Annual Sales, $ 434,250 K
  • Annual Income, $ -606,640 K
  • EBIT $ -549 M
  • EBITDA $ -536 M
  • 60-Month Beta 0.58
  • Price/Sales 10.82
  • Price/Cash Flow N/A
  • Price/Book 10.87

Options Overview Details

View History
  • Implied Volatility 60.80% ( -1.01%)
  • Historical Volatility 25.46%
  • IV Percentile 80%
  • IV Rank 34.26%
  • IV High 110.63% on 04/12/24
  • IV Low 34.83% on 12/22/23
  • Put/Call Vol Ratio 6.00
  • Today's Volume 7
  • Volume Avg (30-Day) 55
  • Put/Call OI Ratio 0.58
  • Today's Open Interest 12,598
  • Open Int (30-Day) 13,711

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -1.45
  • Number of Estimates 11
  • High Estimate -1.18
  • Low Estimate -1.71
  • Prior Year -2.23
  • Growth Rate Est. (year over year) +34.98%

Price Performance

See More
Period Period Low Period High Performance
1-Month
49.84 +2.45%
on 11/04/24
57.99 -11.96%
on 10/16/24
-2.73 (-5.08%)
since 10/04/24
3-Month
45.70 +11.73%
on 08/05/24
60.37 -15.42%
on 09/16/24
+0.59 (+1.17%)
since 08/02/24
52-Week
34.06 +49.91%
on 11/13/23
60.37 -15.42%
on 09/16/24
+12.23 (+31.50%)
since 11/03/23

Most Recent Stories

More News
Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update

RARE : 51.06 (+0.14%)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RARE : 51.06 (+0.14%)
Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta

RARE : 51.06 (+0.14%)
RARE's Wilson Disease Candidate Betters Standard Therapy in Study

Ultragenyx Pharmaceutical RARE reported positive updates from the Stage 1 cohorts of its phase I/II/III Cyprus2+ study evaluating UX701, an investigational AAV9 gene therapy, to treat Wilson disease. Stage...

KRYS : 170.85 (-3.14%)
RARE : 51.06 (+0.14%)
FULC : 3.26 (+1.56%)
ANIP : 56.01 (-3.75%)
Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

RARE : 51.06 (+0.14%)
Ultragenyx: Q2 Earnings Snapshot

Ultragenyx: Q2 Earnings Snapshot

RARE : 51.06 (+0.14%)
1 Biotech Stock to Buy for 104% Upside Potential

Ultragenyx Pharmaceuticals is a beaten-down biotech stock trading at a steep discount to consensus price target estimates.

RARE : 51.06 (+0.14%)
GS : 511.47 (-1.52%)
Ultragenyx: Q1 Earnings Snapshot

Ultragenyx: Q1 Earnings Snapshot

RARE : 51.06 (+0.14%)
Ultragenyx: Q4 Earnings Snapshot

Ultragenyx: Q4 Earnings Snapshot

RARE : 51.06 (+0.14%)
Ultragenyx: Q3 Earnings Snapshot

Ultragenyx: Q3 Earnings Snapshot

RARE : 51.06 (+0.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ultragenyx Pharmaceutical Inc. is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.

See More

Key Turning Points

3rd Resistance Point 53.84
2nd Resistance Point 52.79
1st Resistance Point 51.93
Last Price 51.06
1st Support Level 50.02
2nd Support Level 48.97
3rd Support Level 48.11

See More

52-Week High 60.37
Last Price 51.06
Fibonacci 61.8% 50.32
Fibonacci 50% 47.22
Fibonacci 38.2% 44.11
52-Week Low 34.06

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar